ストックスクリーナーアプリを入手
737.00
4.87%
34.25
アフターアワーズ：
739.01
2.01
+0.27%
前日終値:
$702.75
開ける：
$725
24時間の取引高:
2.28M
Relative Volume:
2.11
時価総額：
$76.77B
収益：
$14.25B
当期純損益:
$4.58B
株価収益率:
17.64
EPS:
41.7701
ネットキャッシュフロー:
$3.88B
1週間 パフォーマンス:
+6.04%
1か月 パフォーマンス:
+27.78%
6か月 パフォーマンス:
+19.88%
1年 パフォーマンス:
-0.85%
1日の値動き範囲:
$720.02
$753.51
1週間の範囲:
$685.95
$753.51
52週間の値動き範囲:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
FDA Approves Aflibercept Injection for Macular Edema Following Retinal Vein Occlusion - Drug Topics
Novartis, Moderna detail manufacturing expansions in the US, among others - Endpoints News
Regeneron wins 2 Eylea nods, ramping up competition with Roche - Fierce Pharma
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Benzinga
With new approvals, Regeneron’s higher-dose Eylea gets more competitive - BioPharma Dive
Wells Fargo Raises Price Target for REGN to $700 | REGN Stock News - GuruFocus
EC approval for Libtayo as adjuvant treatment of high-risk CSCC - The Pharma Letter
Seizert Capital Partners LLC Has $45.14 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Hands Regeneron Two Eylea HD Nods in One Day - BioSpace
Bernstein reiterates Outperform rating on Regeneron stock at $818 - Investing.com India
Regeneron’s Eylea franchise boosted by pair of FDA approvals - Yahoo Finance
United States AMD Drug Market 2025: Get Exclusive Data | Top 5 - openPR.com
Intrust Bank NA Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Raymond James Adjusts PT on Regeneron Pharmaceuticals to $800 From $723, Keeps Outperform Rating - MarketScreener
Nomura Asset Management Co. Ltd. Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is favored by hedge fundsProfit Target & Weekly Momentum Stock Picks - newser.com
Rockefeller Capital Management L.P. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meridian Wealth Management LLC Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron - The Wall Street Journal
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetTreasury Yields & Daily Market Momentum Tracking - newser.com
Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stockQuarterly Profit Review & Capital Efficiency Focused Strategies - newser.com
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsMarket Volume Report & Advanced Swing Trade Entry Plans - newser.com
Stocks to Watch : Nvidia, Kulicke & Soffa, Regeneron - MarketScreener
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection - GuruFocus
Regeneron Announces Plans To Establish New Drug Manufacturing Facility In Saratoga Springs NY - Pharmaceutical Online
Regeneron Gets FDA Approval for Eylea to Treat Macular Edema - MarketScreener
Regeneron gets FDA nod for Eylea in macular edema treatment - Seeking Alpha
FDA Approves Eylea HD Injection from Regeneron (REGN) for Eye Conditions - GuruFocus
FDA approves EYLEA HD for retinal vein occlusion with extended dosing - Investing.com Canada
Regeneron stock rises as EYLEA HD gets FDA approval for new indication - Investing.com Canada
Regeneron Announces FDA Approval of EYLEA HD® for Retinal Vein Occlusion with New Dosing Options - Quiver Quantitative
Regeneron (NASDAQ: REGN) secures FDA approval for EYLEA HD in RVO with 8-week option and monthly dosing - Stock Titan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
What does recent volatility data suggest for Regeneron Pharmaceuticals Inc.IPO Watch & Risk Managed Investment Signals - newser.com
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockMarket Volume Summary & Reliable Momentum Entry Alerts - newser.com
Regeneron to Invest More Than $2 Billion to Double Pharmaceutical Manufacturing Capacity in New York State - Design and Development Today
Can Regeneron Pharmaceuticals Inc. stock hit record highs again2025 AllTime Highs & Detailed Earnings Play Alerts - newser.com
Regeneron (REGN) Gains EU Approval for Expanded Use of Libtayo - GuruFocus
Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recoveryWeekly Investment Summary & Low Volatility Stock Recommendations - newser.com
Regeneron gets EU nod for expanded approval of Libtayo (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo - MarketScreener
European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc - MarketScreener
REGN: European Approval for Regeneron's Libtayo in Skin Cancer T - GuruFocus
Regeneron (REGN) EC Approves Libtayo as First Adjuvant CSCC Immunotherapy, 68% Risk Cut - Stock Titan
How Regeneron Pharmaceuticals Inc. stock responds to policy changesMarket Volume Summary & Weekly High Conviction Ideas - newser.com
United States Bispecific T-cell Engagers (BiTEs) Market Size, - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Raiffeisen Bank International AG - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by ARS Investment Partners LLC - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock weather global recessionStop Loss & Growth Focused Investment Plans - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
3.25%
0.43%
大文字化:
|
ボリューム (24 時間):